Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Imlunestrant - Eli Lilly and Company/Loxo-Oncology

Next Previous
Drug Profile

Imlunestrant - Eli Lilly and Company/Loxo-Oncology

Alternative Names: IMULURIO; Inluriyo; LY-3484356

Latest Information Update: 23 Sep 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eli Lilly and Company
  • Class Antineoplastics; Azetidines; Benzopyrans; Fluorinated hydrocarbons; Heterocyclic compounds with 4 or more rings; Phenyl ethers; Quinolines; Small molecules
  • Mechanism of Action Estrogen receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed HER2 negative breast cancer
  • No development reported Endometrial cancer

Most Recent Events

  • 18 Sep 2026 Registered for HER2-negative-breast-cancer (Late-stage disease, Combination therapy, Metastatic disease, Second-line therapy or greater) in USA (PO)
  • 28 Jul 2026 No recent reports of development identified for phase-I development in Endometrial-cancer(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Australia (PO)
  • 28 Jul 2026 No recent reports of development identified for phase-I development in Endometrial-cancer(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Belgium (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top